Bulletin du Cancer Template
Write in a clean editor, then format for Bulletin du Cancer in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Bulletin du Cancer format
Bulletin du Cancer is a peer-reviewed journal published by Elsevier, covering Health, Medicine and Society, Cancer Treatment and Pharmacology, Colorectal Cancer Treatments and Studies.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Bulletin du Cancer 12 (2023) 45–58.
Formats any DOI in Bulletin du Cancer style. No sign-up. |
| Publishes research in | Health, Medicine and Society Cancer Treatment and Pharmacology Colorectal Cancer Treatments and Studies Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers |
| ISSN | 0007-4551 |
| Citation impact (2-yr) | 0.4 |
| h-index | 38 |
| i10-index | 495 |
| Total citations | 17,641 |
| Article processing charge | $1,790 |
| Top institutions publishing here | Inserm |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Bulletin du Cancer per year
Citation impact of Bulletin du Cancer by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Bulletin du Cancer
Exosomes are now considered to be involved in mediating cell-to-cell communication to promote or inhibit tumor progression. However, the role and molecular mechanism of exosomes in promoting glioblastoma (GBM) metastasis remains elusive. Here, we found that circulating exosomal miR-148a levels were significantly higher in serum from GBM patients compared with serum from healthy volunteers. In…
Les fluoropyrimidines restent les molécules anticancéreuses les plus prescrites dans le traitement des tumeurs solides. Elles induisent des toxicités sévères chez 10–40 % des patients et des toxicités létales chez 0,2–0,8 % des patients. Une abondante littérature a établi le lien entre un déficit enzymatique en dihydropyrimidine déshydrogénase (DPD, enzyme qui dégrade le 5-FU) et…